Anti-carcinoembryonic antigen-related cell adhesion molecule antibody for fluorescence visualization of primary colon cancer and metastases in patient-derived orthotopic xenograft mouse models.
CEACAM
carcinoembryonic antigen
colon cancer
fluorescence
near-infrared
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
28 Jan 2020
28 Jan 2020
Historique:
received:
25
09
2019
accepted:
04
01
2020
entrez:
18
2
2020
pubmed:
18
2
2020
medline:
18
2
2020
Statut:
epublish
Résumé
Monoclonal antibody (mAb) 6G5j is a novel anti-CEACAM monoclonal antibody. Our aim was to investigate mAb 6G5j binding characteristics and to validate fluorescence targeting of colorectal tumors and metastases in patient derived orthotopic xenograft (PDOX) models with fluorescently labeled 6G5j. The MAb 6G5j binding profile was analyzed with ELISA, Western blot and immunohistochemistry. MAb 6G5j was conjugated to near-infrared dye IR800CW (LI-COR). Western blotting was performed with various colon cancer cell lysates to determine CEACAM expression. Nude mice received orthotopic implantation of patient-derived primary colon cancer and patient-derived colon cancer metastases. Mice were administered varying doses of 6G5j-IR800CW via tail vein injection and imaged 24 and 48 hours later. MAb 6G5j bound to human CEACAM1, 3, 5, 6 and 8. Western blotting demonstrated varied expression of CEACAMs in 15 of 16 colon cancer lysates. Dose and time-response imaging demonstrated optimal imaging 48 hours after administration of 50 μg 6G5j-IR800CW (Tumor-to-liver ratio (TLR) 3.17, SEM ± 0.45). Primary cancers and multiple metastases were fluorescently visualized. Anti-CEACAM antibody 6G5j binds multiple CEACAMs which may lead to improved detection of tumor margins for tumors and metastases that have variable expression of CEA and other CEACAMs. 6G5j mAb may be useful for colon cancer detection for pre-surgical diagnosis and fluorescence-guided surgery.
Sections du résumé
BACKGROUND
BACKGROUND
Monoclonal antibody (mAb) 6G5j is a novel anti-CEACAM monoclonal antibody. Our aim was to investigate mAb 6G5j binding characteristics and to validate fluorescence targeting of colorectal tumors and metastases in patient derived orthotopic xenograft (PDOX) models with fluorescently labeled 6G5j.
MATERIALS/METHODS
METHODS
The MAb 6G5j binding profile was analyzed with ELISA, Western blot and immunohistochemistry. MAb 6G5j was conjugated to near-infrared dye IR800CW (LI-COR). Western blotting was performed with various colon cancer cell lysates to determine CEACAM expression. Nude mice received orthotopic implantation of patient-derived primary colon cancer and patient-derived colon cancer metastases. Mice were administered varying doses of 6G5j-IR800CW via tail vein injection and imaged 24 and 48 hours later.
RESULTS
RESULTS
MAb 6G5j bound to human CEACAM1, 3, 5, 6 and 8. Western blotting demonstrated varied expression of CEACAMs in 15 of 16 colon cancer lysates. Dose and time-response imaging demonstrated optimal imaging 48 hours after administration of 50 μg 6G5j-IR800CW (Tumor-to-liver ratio (TLR) 3.17, SEM ± 0.45). Primary cancers and multiple metastases were fluorescently visualized.
CONCLUSIONS
CONCLUSIONS
Anti-CEACAM antibody 6G5j binds multiple CEACAMs which may lead to improved detection of tumor margins for tumors and metastases that have variable expression of CEA and other CEACAMs. 6G5j mAb may be useful for colon cancer detection for pre-surgical diagnosis and fluorescence-guided surgery.
Identifiants
pubmed: 32064046
doi: 10.18632/oncotarget.27446
pii: 27446
pmc: PMC6996915
doi:
Types de publication
Journal Article
Langues
eng
Pagination
429-439Subventions
Organisme : BLRD VA
ID : I01 BX003856
Pays : United States
Organisme : BLRD VA
ID : I01 BX004494
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA121938
Pays : United States
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST None.
Références
Ann Surg. 2017 Jul;266(1):36-47
pubmed: 28045715
J Clin Oncol. 2017 Oct 10;35(29):3338-3346
pubmed: 28817371
Ann Surg Oncol. 2014 Apr;21(4):1405-11
pubmed: 24499827
Cancer Metastasis Rev. 2013 Dec;32(3-4):643-71
pubmed: 23903773
Lancet Gastroenterol Hepatol. 2018 Mar;3(3):181-191
pubmed: 29361435
Eur Rev Med Pharmacol Sci. 2018 Mar;22(5):1286-1289
pubmed: 29565485
Cancers (Basel). 2019 Mar 13;11(3):
pubmed: 30871206
J Surg Res. 2013 Jan;179(1):87-93
pubmed: 23079571
Nat Commun. 2015 Feb 18;6:6217
pubmed: 25692415
J Cell Biochem. 1994 Sep;56(1):1-3
pubmed: 7806583
Lung Cancer. 2008 Jun;60(3):309-12
pubmed: 18462829
Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9345-9
pubmed: 1924398
Arch Surg. 2012 Sep;147(9):876-80
pubmed: 22987187
Nat Commun. 2018 Jul 2;9(1):2561
pubmed: 29967450
Tumour Biol. 1999 Sep-Oct;20(5):277-92
pubmed: 10436421
Curr Opin Cell Biol. 2006 Oct;18(5):565-71
pubmed: 16919437
Sci Rep. 2018 Apr 9;8(1):5686
pubmed: 29632347
Clin Cancer Res. 2009 Oct 1;15(19):6052-61
pubmed: 19789330
Semin Cancer Biol. 1999 Apr;9(2):67-81
pubmed: 10202129
J Laparoendosc Adv Surg Tech A. 2014 Apr;24(4):241-7
pubmed: 24494971
Br J Cancer. 2013 Feb 19;108(3):662-7
pubmed: 23322207
Proc Natl Acad Sci U S A. 1995 Dec 19;92(26):12085-9
pubmed: 8618849
Exp Cell Res. 2000 Nov 1;260(2):365-73
pubmed: 11035932